SLC26A7 and undifferentiated carcinoma: There is evidence that decreased SLC26A7 expression accompanies the development of anaplastic carcinoma and significantly correlates with a poor prognosis among the patients [26], whereas in PTC, SLC26A7 downregulation has been associated with an elevated risk of metastases outside the thyroid [39].